A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)Key Points: by Maeve A. Hennessy, Ashley Cimino-Mathews, Jodi M. Carter, Jennifer M. Kachergus, Yaohua Ma, Jeffrey P. Leal, Lilja B. Solnes, Vandana G. Abramson, Lisa A. Carey, Mothaffar Rimawi, Jennifer Specht, Anna Maria Storniolo, Christos Vaklavas, Ian Krop, Eric Winer, Rita Denbow, Vincente Valero, Antonio C. Wolff, Richard L. Wahl, Chiung-Yu Huang, Vered Stearns, E. Aubrey Thompson, Roisin M. Connolly

Get full text